July Summary: Largest Psychedelic Compound-Based R&D Stocks Up 16%

The 6 largest  psychedelic compound-based research & development stocks are ranked below as to their performances so far in July:

1. Seelos (SEEL): Up 25.8% so far in July
   • focused on the use of ketamine*. Go here for much more extensive information on Ketamine.
   • current market capitalization: $163M
   • current price/share: $1.51
   • current short interest: 4.5%
   • Read: Description Of Diseases Seelos Therapeutics Is Focused On 
2. Mind Medicine (MNMD): Up 22.1% so far in July
   • is primarily focused on the use of LSD* and MNMA*. Go here for much more extensive information on LSD and  here for much more extensive information on MNMA.
   • current market capitalization: $159M
   • current price/share: $4.36
   • current short interest: 9.2%
   • Read: MindMed Pipeline and Progress To Date 
3. Atai (ATAI): Up 19.8% so far in July
   • focused on the use of ketamine*, DMT* and ibogaine*.  Go here for much more extensive information on Ketamine and here for much more extensive information on DMT.
   • current market capitalization: $339M
   • current price/share: $2.06
   • current short interest: 3.1%
   • Read: Description of 5 Psychiatric Disorders Atai Life Sciences Is Focused On 
4. GH Research (GHRS): Up 18.5% so far in July
   • is primarily focused on the use of mebufotenin*, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine but is better known by its nickname, “The Toad”
   • current market capitalization: $690M
   • current price/share: $14.07
   • current short interest: 10.4%
   • Read: Here's Why We're Not Too Worried About GH Research's (NASDAQ:GHRS) Cash Burn Situation
5. Compass Pathways (CMPS): Up 9.8% so far in July
   • focused on the use of psilocybin* (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin.
   • current market capitalization: $400M
   • current price/share: $9.09
   • current short interest: 14.3% - A high short interest signals that investors have become more bearish and may be getting ready to sell and, as such, that it may be time to liquidate a long position.
   • Read: This Unexpected Development Is Yet Another Green Flag for Compass Pathways Stock
6. Incannex Healthcare (IXHL): Down 1.6% so far in July
   • is researching and developing therapies and products with the world's largest portfolio of medicinal cannabinoid and psychedelic pharmaceutical products. Read: Incannex Healthcare: Has World’s Largest Pipeline Of Psychedelic Programs
   • current market capitalization: $111M
   • current price/share: $1.86
   • current short interest: NA
   • Read: Incannex thrilled with positive pre-IND meeting for arthritis treatment and Incannex Submits IND Application to the US FDA for IHL-42X for Obstructive Sleep Apnoea

*Read 10 Psychedelic Substances And The 36 Companies Researching Them for a description of each of the psychedelic-based compounds mentioned in this article.

Summary

The munKNEE Psychedelic Drug Stocks Index was Up 1.9% this week and is Up 15.7% so far in July.

If you are interested in this category, consider the  AdvisorShares Psychedelic ETF (PSIL) which consists of 23 such stocks - but keep in mind that the vast majority have market capitalizations of $50M or less (i.e. are nano-caps). It was DOWN 1.5% this week but remains Up 6.5% so far in July.

---

More By This Author:

These 9 "Penny" AI Stocks Are Up 43%, On Average, In Just 3 Months
July Summary: Upward Trend In Conservative "Cannabis" Stocks Continues
Tilray Brand Stock Jumps 28% With Release Of Its Q4 Financials